Logo
x

Search

Subscribe Now

mitsubishi tanabe pharma

Mitsubishi Tanabe Pharma America Reports 48-Week P-III Trial (MT-1186-A01) Results of Radicava ORS (edaravone) for Amyotrophic Lateral Sclerosis

Mitsubishi Tanabe Pharma America Reports 48-Week P-III Trial (MT-1186-A01) Results of Radicava ORS (edaravone) for Amyotrophic Lat...

  • February 28, 2023
Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue

Top 20 Immunology Companies Based on 2021 Immunology Segment Total Revenue

  • August 11, 2022
Mitsubishi Tanabe Pharma Reports US FDA Acceptance of NDA for Edaravone (MT-1186) for the Treatment of ALS

Mitsubishi Tanabe Pharma Reports US FDA Acceptance of NDA for Edaravone (MT-1186) for the Treatment of ALS

  • January 13, 2022
Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue

Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue

  • August 12, 2021
Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

  • October 22, 2020
PharmaShots' Most Read News of 2019

PharmaShots' Most Read News of 2019

  • January 10, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.